View on Pubmed.gov 21930769 | View on doi.org 10.1084/jem.201...
Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
- Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Abstract
Cancer immunoediting is the process whereby the immune system suppresses neoplastic growth and shapes tumor immunogenicity. We previously reported that type I interferon (IFN-α/β) plays a central role in this process and that hematopoietic cells represent critical targets of type I IFN's actions. However, the specific cells affected by IFN-α/β and the functional processes that type I IFN induces remain undefined. Herein, we show that type I IFN is required to initiate the antitumor response and that its actions are temporally distinct from IFN-γ during cancer immunoediting. Using mixed bone marrow chimeric mice, we demonstrate that type I IFN sensitivity selectively within the innate immune compartment is essential for tumor-specific T cell priming and tumor elimination. We further show that mice lacking IFNAR1 (IFN-α/β receptor 1) in dendritic cells (DCs; Itgax-Cre(+)Ifnar1(f/f) mice) cannot reject highly immunogenic tumor cells and that CD8α(+) DCs from these mice display defects in antigen cross-presentation to CD8(+) T cells. In contrast, mice depleted of NK cells or mice that lack IFNAR1 in granulocytes and macrophage populations reject these tumors normally. Thus, DCs and specifically CD8α(+) DCs are functionally relevant targets of endogenous type I IFN during lymphocyte-mediated tumor rejection.
References
J Exp Med. 2009 Jul 6;206(7):1589-602
J Immunol. 2009 Jul 15;183(2):1099-109
J Immunol. 2009 Aug 15;183(4):2286-93
J Exp Med. 2009 Dec 21;206(13):3115-30
Cited by 1020 citations (total)
Journal Article
Genuine Immunomodulation With dSLIM.
Electronic publication date June 25, 2014
Kerstin Kapp [...] Burghardt Wittig et al.
Toll-like receptors are sensing modulators of the innate immune system. One member of this protein family, Toll-like receptor (TLR)-9, is...
Journal Article Research Support, N.I.H., Extramural
Host STAT2/type I interferon axis controls tumor growth.
Electronic publication date December 23, 2014
Chanyu Yue [...] Ana M Gamero et al.
The role of STAT2 in mediating the antigrowth effects of type I interferon (IFN) is well-documented in vitro. Yet evidence...
Conflict of interest statement
MeSH
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Substances
- •
- •
- •